MIP-II Antibody (82206) [Alexa Fluor® 700]

• Applications: WB
• Clone: 82206
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

MIP-II Antibody (82206) [Alexa Fluor® 700] Summary

• Immunogen: E. coli-derived recombinant human herpes virus-8 MIP-II
  Leu24-Arg94
  Accession # AAC57093
• Specificity: Detects viral MIP-II in direct ELISAs and Western blots. In direct ELISAs, no cross‑reactivity with recombinant viral (rv) MIP-I, rvCMV UL146, recombinant human MIP-1 alpha or recombinant mouse MIP-1 alpha is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Human herpesvirus-8 (HHV-8)/Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma  herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus. HHV‑8 is etiologically linked to Kaposi’s sarcoma and a B-cell lymphoma known as primary effusion lymphoma. HHV-8 has been shown to encode a variety of immunomodulatory proteins which were apparently pirated from cellular genes by the virus. Three chemokine-like proteins, vMIP-I, vMIP-II and vMIP-III have been found to be encoded within the HHV-8 genome. Viral MIP-II cDNA encodes a 94 amino acid (aa) precursor protein with a 23 aa signal peptide that is cleaved to yield a 71 aa mature protein. Among human chemokines, vMIP-II is most closely related to MIP-1 alpha , sharing approximately 41% amino acid sequence identity. At the amino acid sequence level, vMIP-I and vMIP-II also share 48% identity. vMIP-I and vMIP-II are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. vMIP-II binds to the CCR3 chemokine receptor through which Eotaxin and other beta chemokines activate eosinophils. vMIP-II has been shown to activate and chemoattract human eosinphils. Both vMIP-I and vMIP-II have been shown to partially block HIV infection of peripheral blood mononuclear cells. vMIP-I and vMIP-II have also been found to be highly angiogenic in the chorioallantoic assay, suggesting that they may be partially responsible for the marked vascularity seen in KSHV-associated tumors.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.